Last reviewed · How we verify

Surgery with Naproxen

Giovana Maria Weckwerth · FDA-approved active Small molecule ✓ Verified May 2026

Surgery with Naproxen is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Giovana Maria Weckwerth. It is currently FDA-approved for Post-operative pain and inflammation management, Acute pain following surgical procedures. Also known as: Lower third molar surgery with Naproxen.

Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Naproxen is a small molecule used in multi-modal pain management after outpatient orthopaedic surgery, specifically studied in conditions such as postoperative pain after knee and shoulder arthroscopy. It is one of the interventions being studied in a prospective randomized trial registered on ClinicalTrials.gov.

At a glance

Generic nameSurgery with Naproxen
Also known asLower third molar surgery with Naproxen
SponsorGiovana Maria Weckwerth
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase (COX-1 and COX-2)
ModalitySmall molecule
Therapeutic areaPain Management / Perioperative Care
PhaseFDA-approved

Mechanism of action

Naproxen blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, naproxen provides analgesic and anti-inflammatory effects. When used perioperatively with surgery, it helps manage post-operative pain and inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Surgery with Naproxen

What is Surgery with Naproxen?

Surgery with Naproxen is a Nonsteroidal anti-inflammatory drug (NSAID) drug developed by Giovana Maria Weckwerth, indicated for Post-operative pain and inflammation management, Acute pain following surgical procedures.

How does Surgery with Naproxen work?

Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

What is Surgery with Naproxen used for?

Surgery with Naproxen is indicated for Post-operative pain and inflammation management, Acute pain following surgical procedures.

Who makes Surgery with Naproxen?

Surgery with Naproxen is developed and marketed by Giovana Maria Weckwerth (see full Giovana Maria Weckwerth pipeline at /company/giovana-maria-weckwerth).

Is Surgery with Naproxen also known as anything else?

Surgery with Naproxen is also known as Lower third molar surgery with Naproxen.

What drug class is Surgery with Naproxen in?

Surgery with Naproxen belongs to the Nonsteroidal anti-inflammatory drug (NSAID) class. See all Nonsteroidal anti-inflammatory drug (NSAID) drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid.

What development phase is Surgery with Naproxen in?

Surgery with Naproxen is FDA-approved (marketed).

What are the side effects of Surgery with Naproxen?

Common side effects of Surgery with Naproxen include Gastrointestinal upset / dyspepsia, Increased bleeding risk, Renal impairment, Cardiovascular events (with chronic use).

What does Surgery with Naproxen target?

Surgery with Naproxen targets Cyclooxygenase (COX-1 and COX-2) and is a Nonsteroidal anti-inflammatory drug (NSAID).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing